Abstract -Brain-derived neurotrophic factor (BDNF) is a neurotrophic factor involved in neuronal differentiation, plasticity, survival and regeneration. BDNF draws massive attention mainly due to the potential as a therapeutic target in neurological diseases such as depression and Alzheimer's disease. In a primary screening for the natural compounds enhancing BDNF release from cultured rat primary cortical neuron, we found that compounds such as baicalein, tanshinone IIa, cinnamic acid, epiberberine, genistein and wogonin among many others increased BDNF release. All the compounds at 0.1 μM of concentration barely showed stimulatory effect on BDNF induction, however, their combination (mixture 1; baicalein, tanshinone IIa and cinnamic acid, mixture 2; epiberberine, genistein and wogonin) showed synergistic increase in BDNF release as well as mRNA and protein expression. The level of BDNF expression was comparable to the maximum BDNF stimulation attainable by a positive control oroxylin A (20 μM) without cell toxicity as determined by MTT analysis. Both mixtures synergistically increased the phosphorylation of extracellular signal-regulated kinase (ERK) as well as cAMP response element binding protein (CREB), an immediate and essential regulator of BDNF expression. Similar to these results, mixture of these compounds synergistically inhibited the up-regulation of inducible nitric oxide synthase (iNOS) induced by lipopolysaccharide treatments in rat primary astrocytes. These results suggest that the combinatorial treatment of natural compounds in lower concentration might be a useful strategy to obtain sufficient BDNF stimulation in neurological disease condition such as depression, while minimizing potential side effects and toxicity of higher concentration of a single compound.
INTRODUCTION
Brain-derived neurotrophic factor (BDNF) is a growth factor belongs to neurotrophin family. BDNF plays essential roles in neuronal survival and control of CNS development (Bibel and Barde, 2000) . BDNF initiates cellular response by specific binding to tropomycin receptor kinase B (TrkB) (Soppet et al., 1991) .
Several researchers have reported that BDNF regulates neuronal survival (Sairanen et al., 2005) , neuronal differentiation and synaptic plasticity (Huang and Reichardt, 2001) , which make it important to understand the neurobiology of BDNF in CNS diseases including epilepsy (Hu and Russek, 2008) , depression (Ozan et al., 2009) , obsessive-compulsive disorder (Hemmings et al., 2008) and bipolar disorder (Angelucci et al., 2005) . Therefore, regulating BDNF levels in several neurological diseases would be an effective target for treatments. In facts, several types of anti-depressant reversed the decreased BDNF production in depressive patients (Duman, 2002) . One of the key regulators of BDNF expression is cyclic AMP response element binding protein (CREB). CREB is Se Jin Jeon et al. a nuclear transcription factor, which binds to promoter regions of target DNAs, which is called cyclic AMP response element sequence (CRE), as a homodimer or heterodimer (Maekawa et al., 1989) . The activation of CREB is achieved by the regulation of phosphorylation by mitogen-activated protein kinase (MAPK, Ha and Redmond, 2008) , cAMP-protein kinase A (PKA, Wang et al., 2006) , calcium/calmodulin-dependent protein kinase II/IV (CaMKII/ IV, Sato et al., 2006) , and phospholipase C (PLC) -protein kinase C (PKC, Cramer et al., 2008) .
We recently screened several compounds from medicinal herbs, which have been known to possess neuroprotective effects and found that compounds like baicalein, tanshinone IIa, cinnamic acid, epiberberine, genistein and wogonin increased the production of BDNF from cultured rat primary neuron.
Baicalein and wogonin are flavonoid compounds from the rhizome of medicinal plants such as Scutellaria baicalensis. These compounds increase cognitive function and inhibit the induction of pro-inflammatory cytokines (Chen et al., 2009) . Tanshinone IIa is one of the main ingredients of the roots of Salvia miltiorrhiza with diterpenoid structure. It has been suggested that tanshinone IIa has neuroprotective effects in the animal models of ischemic stroke (Yu et al., 2007) . Cinnamic acid is from the barks of Cinnamomum cassia and possesses core structure of aromatic unsaturated carboxylic acid with neuroprotective effects (Yamashita et al., 2007) . Epiberberine is a major component of Coptis chinensis and has been suggested to have beneficial effects in Alzheimer's disease (Jung et al., 2009) . Genistein can be extracted from several species of plants including Pueraria lobata and possesses flavonoid structure.
Recent reports from several researchers including us suggest that natural compounds from several different species including Angelica gigas and Cassia obtusifolia exert neuroprotective effects at least in part by the up-regulation of BDNF through the regulation of CREB phosphorylation (Cui et al., 2009) . In this study, we tried to examine whether the combination of low concentration of natural compounds has synergistic effects on BDNF expression. The synergistic combinatorial effects of these natural products on BDNF production may provide new approaches to achieve the up-regulation of BDNF while minimizing cellular toxicity or adverse effects of individual compounds.
MATERIALS AND METHODS

Materials
Dulbecco's modified eagle medium (DMEM)/F12, neurobasal medium and fetal bovine serum were purchased from GIBCO BRL (Grand Island, NY, USA 
Cell culture
Cultured cells were prepared from the cerebral cortex of fetal Sprague Dawley (SD) rat at embryonic day 16 as previously described (Park et al., 2009) . Briefly, cortices were dissected and digested with trypsin-ethylenediaminetetraacetic acid (EDTA) solution followed by dissociation with a Pasteur pipette. The dissociated cells were resuspended in neurobasal medium (NBM) containing B-27 supplements and plated onto poly-D-lysine-coated culture dishes. The media were half-replaced with fresh media every 3 days. Cultured cortical neurons were kept for 10-14 days at 37 o C and 10% CO2 incubator before experiments.
Cell viability
Cell viability after treatment of the chemicals was determined by MTT assay. After treatment, cells were treated with the MTT solution (final concentration, 5 μg/ml) for 2 h. The dark blue formazan crystals formed in intact cells were solubilized with lysis buffer (20% sodium dodecylsulfate in 50% aqueous N, N-dimethylformamide). The absorbance of the sample was read at 540-595 nm with a microplate reader (Molecular Devices, Sunnylvale, CA, USA). Results were expressed as the percentage (%) of MTT reduction, assuming that the absorbance of control cells was 100%.
Enzyme linked immunosorbent assay (ELISA)
To measure the BDNF release into the culture spent medium, we used BDNF Emax immunoassay kit (Promega) according to the manufacturer's instruction. First, we coated 96-well plate with anti-BDNF mAb and incubated it overnight at 4 o C. The plates were washed twice with PBS-Tween and added 200 μl of 1X block & sample buffer and then incubated at room temperature for additional 1 hour. After incubation, the plate was washed twice and added 200 μl of the culture supernatants taken from the cultured cells. And then, the plates were incubated overnight at 4 o C with continuous shaking. The next day, af- Table I . Effects of natural compounds on cell viability. Various concentrations of natural compounds or mixture of 0.1 μM of each compound were added to primary rat cortical neurons and the viability of the cells was determined by MTT analysis. MTT signal was expressed as % of control. Data represent mean ± S.E.M (n=3) ter another washing, the anti-human BDNF Ab were added and incubated 2 h. After incubation, the plates were washed twice and anti-IgY HRP were added (light-protected, RT incubation with shaking for 1 h). The reaction was developed with tetramethylbenzidine developer solution and the absorbance was read at 450 nm after stopping the reaction with 1N HCl. The value of sample absorbance was quantitatively analyzed using BDNF standard curve.
Reverse transcription-polymerase chain reaction (RT-PCR)
Total RNA was extracted from the harvested cells using the Trizol Ⓡ (Invitrogen, Carlsbad, CA, USA) reagent and 1 μg of total RNA was converted to cDNA by Superscript II reverse transcriptase (Invitrogen) at 42 o C for 90 min using first-strand cDNA synthesis kit. The PCR amplification was performed using Maxime PCR premix kit (iNtRon, Seongnam, Korea) and was consisted of 30 cycles (94 o C, 1 min; 60 o C, 1 min; 72 o C, 1 min) with the oligonucleotide primers for BDNF and glyceraldehyde 3-phosphate dehydrogenase (GAPDH). The sequence for PCR was as follows.
-BDNF Forward: 5'-ata gga gac cct ccg caa ct-3' Reverse: 5'-ctg cca tgc atg aaa cac tt-3' -GAPDH Forward: 5'-tcc ctc aag att gtc agc aa-3'
Reverse: 5'-aga tcc aca acg gat aca tt-3' The PCR reaction was analyzed by 1% agarose gel electrophoresis and was stained with ethidium bromide.
Western blot
The activation of ERK1/2 and CREB was determined by Western blot using antibodies specific for phosphorylated, active forms of ERK1/2 or CREB. Cells were treated with various combination of test drugs in serum free DMEM and were lysed with 100 μl of 2 x sample buffer (4% w/v SDS, 20% glycerol, 200 mM DTT, 0.1 M Tris-HCl, pH 6.8, and 0.02% bromophenol blue). The samples were fractionated by 10% SDS-PAGE and electrotransferred to nitrocellulose (NC) membrane. The NC membrane was blocked with 1 μg/ml polyvinyl alcohol and then incubated at room temperature for 2 h with monoclonal antibody (mAb) against pERK1/2 or pCREB (Cell Signaling Technology) which was diluted at 1：3,000 in 5% Blotto. After three 10 min washes with PBS containing 0.2% Tween-20 (PBS-T), the NC membranes were incubated with peroxidase-labeled goat anti-mouse or rabbit IgG at room temperature for 2 h. After extensive washing with PBS-T, the membranes were developed by enhanced chemiluminescence (Amersham, Buckinghampshire, UK). As loading controls, Western blot was performed using antibodies against total ERK (Cell Signaling Technology), total CREB (Cell Signaling Technology) as well as β-actin in 1：30,000 dilution (Sigma). The quantification of the band intensity in Western blot was performed by Image J software (1.42 ver.)
Determination of Nitrite production
After treatment, 100 μl of medium from 24 well plates was mixed with the equal volume of Griess reagent (0.1% naphthylethylenediamine dihydrochloride and 1% sulfanilamide in 5% phosphoric acid) in 96 well plates at RT. After 10 min, the absorbance at 540 nm was measured using an UV spectrophotometer (Spectra Fluor, Tecan, Austria).
Statistical analysis
Data were expressed as the means ± S.E.M. and analyzed for statistical significance by using one-way analysis of variance (ANOVA), followed by Newman-Keuls test as a post hoc test. The criteria for statistical significance was p ＜0.01.
RESULTS
We first determined the effects of various natural compounds used in this study on the BDNF production as well as cell viability. We treated rat primary cortical neuron with various concentrations of the test compounds for 24 h. A flavonoid compound, oroxylin A (20 μM) has been reported to increase BDNF production and CREB phosphorylation in rat brain (Kim et al., 2006) and therefore used as a positive control throughout this study. All the compounds used in this study, i.e. baicalein, tanshinone IIa, cinnamic acid, epiberberine, genistein, and wogonin did not show significant neuronal cytotoxicity, which was determined by MTT assay, at concentrations of 0.1, 0.3, and 1.0 μM. To investigate the synergistic effect of these compounds, we mixed three of each compounds at 0.1 μM concentration and in this condition, all the mixtures did not show significant effects on cell viability (Table I) . Oroxylin A (20 μM), used as a positive control, also did not produce significant cytotoxicity (95.2 ± 3.3% as compared with control).
Rat primary cortical neurons were treated with various concentrations of natural compounds for 24 h and the culture supernatants were analyzed for BDNF release by ELISA assay. All six compounds showed modest increase in BDNF release at 1 μM concentration, while 20 μM of oroxylin A, which has been used as a positive control, showed a significant increase in BDNF release (Fig. 1A) . We mixed 0.1 μM of baicalein, tanshinone IIa and cinnamic acid together (mixture 1), and mixed epiberberine, genistein, and wogonin together (mixture 2). Although 0.3 μM of each compound (shown here are cinnamic acid, and epiberberine) showed only marginal effects on BDNF production, if any, both mixtures of 0.1 μM compounds significantly increased BDNF release (Fig. 1B) . These results suggest that co-treatment of natural compounds used in this study has synergistic effects on BDNF release.
One of the key regulators of BDNF production is the activation of CREB, which might be regulated by ERK activation as well as PKA and calcium signaling. We investigated the activation of CREB and ERK pathway by our compounds using Western blot against phospho-specific CREB as well as phospho-specific ERK. Compared to the representative compounds of mixtures 1 (cinnamic acid) and 2 (epiberberine), both mixtures showed significantly higher phospho-ERK level ( Fig. 2A) . Likewise, the level of phopho-CREB was increased about 2-fold compared to each single compound (Fig. 2B) . Interestingly, mixture 2 increased ERK activity compared to single compound by 130% but increased p-CREB activity by 200%, suggesting that the compounds used in mixture 2 may have additional effects on CREB-regulating pathways which is not related to ERK pathways. To check the role of ERK pathway on BDNF production, we pretreated the cells with a MAPK pathway inhibitor U0126, and it reduced the stimulated BDNF induction by mixtures (Fig. 2C) .
Next, we investigated the expression of BDNF by RT-PCR analysis. The expression level of BDNF mRNA was significantly higher in rat primary cortical neurons treated with mixtures 1 and 2 compared with each representative single compound (Fig. 3A) . Consistent with these results the level of BDNF protein, which was determined by Western blot using an antibody specific against BDNF, was significantly increased by the treatment of mixtures 1 and 2 (Fig. 3B) . These results suggest that the increase in BDNF release is mainly regulated at the level of transcriptional control. Altogether, these results suggest that natu- ral compounds used in this study have synergistic effects on BDNF expression and release by mechanism involving the synergistic activation of key intracellular signaling pathways such as ERK and CREB.
Since many natural products as well as six compounds used in our experiments had been known for anti-oxidative effects including inhibition of iNOS expression, we also examined whether the mixtures have synergistic inhibitory effect on LPS-stimulated iNOS production in rat primary astrocytes. We stimulated rat primary astrocytes with lipopolysaccharide (LPS, 0.2 μg/ml), a well known astrocyte and microglial activator, to induce inducible nitric oxide synthase (iNOS) over-expression. LPS, as reported previously, by itself or in combination with other cytokines including interferon-γ induces iNOS production in rat glial cells (Bhat et al., 1998) . The over-expression of iNOS and nitrite production was not inhibited by 0.3 μM single compounds (cinnamic acid and epiberberine), however, pretreatment of the cells with mixture 1 or mixture 2 completely prevented the over-production of nitrite and iNOS (Fig. 4) . These results suggest that the combination of these compounds also showed synergistic antioxidant effects in LPS-stimulated astrocytes.
DISCUSSION
BDNF is a member of neurotrophic factors involved in the regulation of neuronal survival (Sairanen et al., 2005) , synaptic function, synaptic plasticity as well as neuronal differentiation (Huang and Reichardt, 2001 ). In addition, it is essential for the normal development of neuron (Ernfors et al., 1995) and provide beneficial effect in several neurological disease states including depression (Duman et al., 1997) , schizophrenia (Sasaki et al., 1997) as well as neurodegenerative diseases such as Huntington disease, Alzheimer disease and Parkinson disease (Zuccato and Cattaneo, 2009) . Although originally discovered in brain and hence it gets the name BDNF, it is also found in PNS (Conner et al., 1997) . In brain, BDNF is highly expressed in structures involved in learning and memory and higher executive functions (Hofer et al., 1990) .
In our initial screening of natural compounds modulating BDNF release in rat primary cortical neuron, six compounds used in this study showed increased BDNF release at more than 1 μM concentrations (data not shown). These compounds have been reported to have either neuroprotective or anti-oxidative effects (Kim and Kim, 2000; Piao et al., 2004; Xia et al., 2005; Jung et al., 2009; Mu et al., 2009; Yu et al., 2009 ). However, not all natural compounds having neuroprotective or anti-oxidative effects showed increased BDNF release. For example, a flavonoid or a lignan compound such as benzoylpaeniflorin and phylligenin, which have relatively strong anti-inflammatory and anti-oxidative effects, did not increase BDNF release (data not shown) suggesting simple anti-oxidative properties are not sufficient for the increased BDNF release. Consistent with this speculation, we did not find any common structural determinants to mediate BDNF release in the six compounds tested in this study.
Considering the structural diversities of the six compounds tested in this study, it is reasonable assumption that these compounds regulate different subsets of receptors and intracellular signaling pathways, which mediates the phosphorylation of CREB, a common denominator of the increased BDNF production and release. Currently, four major pathways including cAMP-PKA, MAPKp90 ribosomal S6 kinase (RSK), Ca 2＋ -CAMKII and PLC-PKC have been suggested to modulate CREB phosphorylation and BDNF production. Interestingly, mixture 2 increased the phosphorylation of CREB as much as mixture 1, however, the effects on the phosphorylation of ERK was weaker than that of mixture 1, suggesting that the ingredients in mixture 2 (epiberberine, genistein, and wogonin) may have stimulatory effects on other pathways in addition to ERK pathway. Regarding the activation of ERK, it has been suggested that neurotrophic factors acting on TrkB including BDNF and NT-4 can activate ERK phosphorylation, thereby forming auto-regulatory feed-forward activating loop of BDNF expression (Rumajogee et al., 2002) . It should be investigated in the future whether compounds used in this study, especially mixture 1 (baicalein, tanshinone IIa and cinnamic acid) may modulate the production of other growth factors as well.
Regarding the synergistic mechanism of combinatorial use of natural products, four major mechanisms have described (Wagner and Ulrich-Merzenich, 2009 ). First, the synergistic effects may involve activation of multiple targets. The second is pharmacokinetic effect, in which solubility, resorption rate or bioavailability is increased. Third, the interaction of compounds may lead to the resistance against bacterial degradation. Fourth and the last, the combination of compounds may produce neutralization or elimination of the toxic action or adverse effects of other compounds. In this study, the most plausible explanation of the observed synergistic effects is the cooperative activation of multiple targets by the constituents of the mixture. Drug targets include enzymes, substrates, metabolites, proteins, receptors, ion channels, transport proteins, DNA/ RNA, ribosome, monoclonal antibodies and still unknown mechanism (Imming et al., 2006) . Although we do not know exactly what is the principal targets of the each compounds used in this study, it is obvious that if these molecules share a single target, we might expect simple additive effects or less than additive effects depending on the level of saturation of the target. The structural diversity of the molecules and several reports suggesting the activation of many different signaling pathways such as cAMP-PKA (Wang et al., 2006) , PLC-PKC (Cramer et al., 2008) , ERK-RSK (Ha and Redmond, 2008) and Ca 2＋ -CAMKII (Sato et al., 2006) by these compounds, which is essential for CREB phophorylation and BDNF production, additionally support the idea of synergistic action by activation of multiple targets.
Using mixtures of reagents as a therapeutic agents has several advantages over using a single compound in higher concentration (Wagner and Ulrich-Merzenich, 2009 ). First of all, we can use a significantly low dose of drugs to achieve similar pharmacological effects. While administration of 0.3 μM of cinnamic acid or epiberberine showed only marginal increase in BDNF production, combining three compounds together at 0.1 μM each concentration showed comparable increase in BDNF release to 20 μM oroxylin A, a positive control. The smaller amount of drug with similar or superior activity means that less toxicity or adverse effects might be achieved with the combination of synergistic drugs. In ischemic stroke, it has been suggested that the combined use of a gamma-aminobutyric acid (GABA) agonist and a glutamate antagonist provides synergistic neuroprotective effect (Lyden et al., 2000) . Similarly, the combined use of the drugs used in bipolar disorder such as valproic acid and lithium showed neuroprotective effects both in vivo and in vitro (Feng et al., 2008) . Likewise, synergistic action of combined treatment of several neurotrophin family members together on spinal cord injury (Novikova et al., 2000) and combination of N-methyl D-aspartate (NMDA) and α-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate (AMPA) receptor antagonists on acute ischemic injury have been reported .
Taken together, the combinatorial treatment of several natural compounds to rat primary cortical neuron produced synergistic stimulatory effects on BDNF production and release. With the treatment of lower concentrations of each compound, while retaining similar pharmacological effects, this approach may provide one way to minimize cellular toxicity and adverse effects in the treatment of neurodegenerative diseases and psychological diseases such as depression. The next step will be the delineation of the specific signaling pathways involved in the regulation of BDNF production by each single compound and the molecular mechanism underlying the synergistic effects.
